Aradigm Corporation - Company & Market Research Reports

Aradigm is an emerging specialty pharmaceutical company developing and commercializing a portfolio of drugs delivered by inhalation for the treatment of severe respiratory disease. The company’s lead development candidates are proprietary formulations of the potent antibiotic ciprofloxacin, including Linhaliq (ARD-3150) and Lipoquin (ARD-3100) that are delivered by inhalation for the management of infections associated with severe respiratory diseases, including non-cystic fibrosis bronchiectasis and cystic fibrosis. Aradigm Corporation was founded in 1991 and is headquartered in Hayward, California.

From
From
From
From
Smoking Addiction - Pipeline Review, H2 2017 - Product Thumbnail Image

Smoking Addiction - Pipeline Review, H2 2017

  • Drug Pipelines
  • 89 Pages
From
Smoking Addiction - Pipeline Review, H1 2017 - Product Thumbnail Image

Smoking Addiction - Pipeline Review, H1 2017

  • Drug Pipelines
  • 86 Pages
From
From
Bronchiectasis - Pipeline Review, H2 2018 - Product Thumbnail Image

Bronchiectasis - Pipeline Review, H2 2018

  • Drug Pipelines
  • 88 Pages
From
Bronchiectasis - Pipeline Review, H1 2018 - Product Thumbnail Image

Bronchiectasis - Pipeline Review, H1 2018

  • Drug Pipelines
  • 75 Pages
From
From
From
From
From
From
From
Loading Indicator
adroll